Vision Drugs Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 15-05-2024
- Paid Up Capital ₹ 6.89 Cr
as on 15-05-2024
- Company Age 19 Year, 23 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 102.93 Cr
as on 15-05-2024
- Satisfied Charges ₹ 9.14 Cr
as on 15-05-2024
About Vision Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 6.89 Cr.
The company currently has active open charges totaling ₹102.93 Cr. The company has closed loans amounting to ₹9.14 Cr, as per Ministry of Corporate Affairs (MCA) records.
Battula Sheshu, Haritha Polsani, and Ram Rao serve as directors at the Company.
- CIN/LLPIN
U99999TG2005PTC048204
- Company No.
048204
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Vision Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ram Rao  | Managing Director | 13-Aug-2009 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Battula Sheshu | Director | 02-Feb-2022 | Current |
| Haritha Polsani | Director | 28-Aug-2012 | Current |
Financial Performance and Corporate Structure Insights of Vision Drugs.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Vision Drugs?
Unlock access to Vision Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Dr. Battula's Life Sciences Private LimitedActive 4 years 10 monthsBattula Sheshu is a mutual person
- Phrm Chemicals Private LimitedActive 18 years 5 months
Haritha Polsani and Ram Rao are mutual person
- Sri Venkata Sai Minerals Private LimitedActive 28 years 6 months
Haritha Polsani and Ram Rao are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 17 Nov 2021 | ₹1.25 Cr | Open |
Hdfc Bank Limited Creation Date: 16 Sep 2021 | ₹5.97 M | Open |
Hdfc Bank Limited Creation Date: 14 Dec 2020 | ₹6.00 M | Open |
How Many Employees Work at Vision Drugs?
Unlock and access historical data on people associated with Vision Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vision Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vision Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
